Cargando…

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia

In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (<15 mg/kg/day) are b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Maggio, Rosario, Hsieh, Matthew M., Zhao, Xiongce, Calvaruso, Giuseppina, Rigano, Paolo, Renda, Disma, Tisdale, John F., Maggio, Aurelio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877542/ https://www.ncbi.nlm.nih.gov/pubmed/29495591 http://dx.doi.org/10.3390/ijms19030681

Ejemplares similares

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
por: Ghasemi, A, et al.
Publicado: (2014)

Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia
por: Fitzhugh, Courtney D., et al.
Publicado: (2015)

Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea
por: Khavari, Maryam, et al.
Publicado: (2014)

Study on Hydroxyurea Response in Hemoglobinopathies Patients Using Genetic Markers and Liquid Erythroid Cultures
por: Sclafani, Serena, et al.
Publicado: (2016)

Comparative Study of Radiographic and Laboratory Findings Between Beta Thalassemia Major and Beta Thalassemia Intermedia Patients With and Without Treatment by Hydroxyurea
por: Abolhasani Foroughi, Amin, et al.
Publicado: (2015)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients
por: Bordbar, Mohammad Reza, et al.
Publicado: (2014)

Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea
por: Zekavat, Omid Reza, et al.
Publicado: (2014)

Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia
por: Ansari, Saqib H., et al.
Publicado: (2022)

P1453: ORTHOTOPIC LIVER TRANSPLANT IN SICILIAN HEMOGLOBINOPHATIES PATIENTS
por: Barone, Rita, et al.
Publicado: (2023)

Sickle Cell Beta-Plus Thalassemia with Subcapsular Hematoma of the Spleen
por: Dahal, Suyash, et al.
Publicado: (2017)

Non-Transfusion-Dependent Thalassemia: A Complex Mix of Genetic Entities Yet to Be Fully Discovered
por: Ricchi, Paolo, et al.
Publicado: (2015)

Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan
por: Akram, Sumera, et al.
Publicado: (2022)

In Utero Haematopoietic Stem Cell Transplantation (IUHSCT)
por: Renda, Maria Concetta, et al.
Publicado: (2009)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Microcytic Anemia: An Insidious Presentation of Sickle Cell Beta+ Thalassemia, a Rare Sickle Cell Variant
por: Shankar, Malavika, et al.
Publicado: (2022)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Frequency distribution of sickle cell anemia, sickle cell trait and sickle/beta-thalassemia among anemic patients in Saudi Arabia
por: Elsayid, Mohieldin, et al.
Publicado: (2015)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

P1467: THE EMPLOYMENT OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY Β-THALASSEMIA: A MULTICENTER ANALYSIS FROM THE EXTENSION-MYOCARDIAL IRON OVERLOAD IN THALASSEMIA NETWORK (E-MIOT)
por: Raso, Simona, et al.
Publicado: (2023)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia
por: Lebensburger, Jeffrey D, et al.
Publicado: (2015)

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea
por: Ward, Joel, et al.
Publicado: (2018)

Pure Erythroid Leukemia in a Sickle Cell Patient Treated with Hydroxyurea
por: Yadav, Dhiraj Kumar, et al.
Publicado: (2020)

Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach
por: Nazon, Charlotte, et al.
Publicado: (2019)

Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy
por: Queiroz, Ana Mach, et al.
Publicado: (2021)

A systematic review on hydroxyurea therapy for sickle cell disease in India
por: Pandey, Apoorva, et al.
Publicado: (2022)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Parvovirus Infection and Thrombotic Thrombocytopenic Purpura in an Adult Patient With Sickle Cell Beta-Thalassemia
por: Shaik, Likhita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s5ujfmd14a6femqu09lhmpl3ei